ArticleAmerican journal of clinical oncology2013
Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.
Article in American journal of clinical oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04176809 (Impact of Routine Assessment of Health-Related Quality of Life Coupled With Therapeutic Information on Compliance With Endocrine Therapy in Patients With Non-metastatic Breast Cancer), which is not on this map. Cited by 43 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Routine Assessment of Health-Related Quality of Life Coupled With Therapeutic Information on Compliance With Endocrine Therapy in Patients With Non-metastatic Breast Cancer
Who cites it
43 citing papers in PubMed, 5 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Importance of endocrine treatment adherence and persistence in breast cancer survivorship: a systematic review.BMC cancer · 2023Pooled it
- The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review.Breast (Edinburgh, Scotland) · 2022Pooled it
- The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A qualitative systematic review and thematic synthesis.Breast (Edinburgh, Scotland) · 2021Pooled it
- A Systematic Review of Adherence to Oral Antineoplastic Therapies.The oncologist · 2016Pooled it
- Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review.Breast cancer research and treatment · 2012Pooled it
- Identification of factors associated with non-adherence to oral endocrine therapy in breast cancer patients of low socioeconomic status: a single centre retrospective study.International journal of clinical pharmacy · 2026Article
- Interventions to improve adherence to oral endocrine therapy for prevention or treatment of breast cancer in Black women of low socioeconomic status.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Identifying Complex Scheduling Patterns Among Patients With Cancer With Transportation and Housing Needs: Feasibility Pilot Study.JMIR cancer · 2025Article
- Adherence to adjuvant endocrine therapy after breast cancer in Sweden - a nationwide cohort study in 1-, 3- and 5-year survivors with a focus on regional differences.Acta oncologica (Stockholm, Sweden) · 2024Article
- Association between trajectories of adherence to endocrine therapy and risk of treated breast cancer recurrence among US nonmetastatic breast cancer survivors.British journal of cancer · 2024Article
- Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data.Patient preference and adherence · 2024Article
- Digging in real-word electronic database for assessing CDK 4/6 inhibitors adherence in breast cancer patients from Romania.Frontiers in pharmacology · 2024Article
- Survival benefits associated with being adherent and having longer persistence to adjuvant hormone therapy across up to five years among U.S. Medicare population with breast cancer.Breast cancer research and treatment · 2023Article
- Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests.International journal of molecular sciences · 2022Review
- Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study.European journal of breast health · 2022Review
- Endocrine therapy initiation among women with stage I-III invasive, hormone receptor-positive breast cancer from 2001-2016.Breast cancer research and treatment · 2022Article
- Assessment of compliance with hormonal therapy in early breast cancer patients with positive hormone receptor phenotype: A single institution study.Breast (Edinburgh, Scotland) · 2022Article
- Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study.Breast (Edinburgh, Scotland) · 2021Article
- Development of health behaviour questionnaire for breast cancer women in Mainland China.Nursing open · 2021Review
- Race and Patient-reported Symptoms in Adherence to Adjuvant Endocrine Therapy: A Report from the Women's Hormonal Initiation and Persistence Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesAlthough clinical trials have demonstrated the benefit of adjuvant hormonal therapy for hormone receptor-positive breast cancer, it is not known whether poor medication adherence might impact outcomes, particularly in the context of a low-income population traditionally underrepresented in clinical trials. We explored the relationship between adherence to tamoxifen or selective aromatase inhibitors with cancer recurrence and death in a low-income, Medicaid-insured population.
methodsUsing a Medicaid claims-tumor registry and National Death Index data, we evaluated adherence to adjuvant hormonal therapy [defined by the medication possession ratio (MPR)], cancer recurrence, and cancer-specific survival for female breast cancer diagnosed from 1998 to 2002, in North Carolina. Multivariate Cox proportional hazards models and logistic regression models were used to examine the role of adherence on cancer recurrence and survival.
resultsThe sample consisted of 857 cases, mean age 67.7 years, 56.9% white, 60.9% local stage, with a mean follow-up of 4.4 years. Mean first-year MPR was 77%. MPR adherence was not significantly associated with cancer-related death [adjusted hazards ratio=1.18 (95% confidence interval, 0.54-2.59)], or recurrence [adjusted odds ratio=1.49 (95% confidence interval, 0.78-2.84)]. There was also no significant interaction between adherence and use of concurrent CYP2D6 enzyme inhibitors. DISCUSSION: Hormonal therapy adherence was not associated with breast cancer outcomes in this low-income population with relatively poor adherence. Although suboptimal adherence is considered to be an important clinical problem, its effects on breast cancer outcomes may be masked by patient genetic profiles, tumor characteristics, and behavioral factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.